



CONCORD DRUGS LIMITED

(A PHARMACEUTICAL FORMULATIONS UNIT)

CORPORATE OFFICE : # 3-11-1/1, L.B. Nagar, Hyderabad - 500 074. A.P. India.

Tel : 091-40-24037763, 24036379

Statement of Unaudited Results for the Quarter Ended 31ST DECEMBER, 2013							Rs' Lakhs
Part I		Standalone					
Sl. No.	Particulars	3 months Ended	3 months Ended	3 months Ended	9 months Ended	9 months Ended	Year Ended
		31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.3.2013
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
1	Income from Operations :						
	(a) Net Sales / Income from Operations	881.25	815.30	704.21	2,456.68	2,095.67	2,806.73
	(b) Other Operating Income	3.70	2.89	-	7.89	-	-
	Total Income From operations (net)	884.95	818.19	704.21	2,464.57	2,095.67	2,806.73
2	Expenses :						
	a) Cost of Material Consumed	33.26	29.21	14.24	83.72	41.45	56.74
	b) Purchases of stock in trade	715.95	662.36	561.21	2,003.38	1,742.68	2,345.64
	c) Changes in inventories of finished goods Work-in-progress and stock-in-goods	(2.50)	(2.12)	0.25	(5.82)	(0.15)	0.21
	d) Employee benefits expenses	12.05	12.25	8.56	33.54	23.65	32.47
	e) Depreciation and amortisation expenses	30.25	26.28	17.35	81.78	52.05	71.70
	f) Power And Fuel	12.24	13.26	11.35	37.86	32.86	44.10
	g) Freight and Forwarding Expenses	4.78	3.96	3.92	11.98	11.42	15.15
	h) Other Expenses	20.95	20.36	20.18	62.56	58.31	80.98
	Total Expenses (a+b+c+d+e+f+g+h)	826.98	765.56	657.06	2,308.99	1,962.27	2,646.99
3	Profit from operations before other Income and Finance costs (1-2)	57.97	52.64	47.15	155.58	133.40	159.74
4	Other Income	-	-	-	-	-	-
5	(3+/-)4	57.97	52.64	47.15	155.58	133.40	159.74
6	Finance cost	47.25	42.25	13.35	125.13	37.87	51.61
7	Profit/(Loss) from ordinary activities before Tax (5+/-)6	10.72	10.39	33.80	30.45	95.53	108.13
8	Tax expenses:						(35.32)
	(a) Current Tax	-	-	-	-	-	39.33
	(b) Deferred Tax	2.00	2.00	10.00	6.00	30.00	4.01
	Total (a+b)	2.00	2.00	10.00	6.00	30.00	4.01
9	Net profit/(loss) for the period (7+/-)8	8.72	8.39	23.80	24.45	65.53	104.13
10	Minority interest	-	-	-	-	-	-
11	Net Profit after Taxes and minority interest (9-10)	8.72	8.39	23.80	24.45	65.53	104.13
12	Paid up Equity Share Capital (Face value of `10 /- per share)	724.38	724.38	724.38	724.38	724.38	724.38
13	Reserves excluding Revaluation Reserve as per balance sheet	-	-	-	-	-	503.81
14	Earnings Per Share (of `10/- each) (not annualised)						
	a) Basic	0.12	0.12	0.33	0.34	0.90	1.44
	b) diluted	0.12	0.12	0.33	0.34	0.90	1.44



Part II		Select Information for the Quarter ended 31st Dec, 2013					
Sl. No.	Particulars	3 months Ended	3 months Ended	3 months Ended	9 months Ended	9 months Ended	Year Ended
		31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.3.2013
1	Public Shareholding						
	- Number of shares	4403250	4403250	4403250	4403250	4403250	4403250
	- Percentage of Shareholding	60.79%	60.79%	60.79%	60.79%	60.79%	60.79%
2	Promoter and Promoter group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	--	--	--	--	--	--
	-Percentage of shares to promoter group	--	--	--	--	--	--
	- Percentage of shares to total capital	--	--	--	--	--	--
	b) Non-Encumbered						
	- Number of Shares	2840500	2840500	2840500	2840500	2840500	2840500
	-Percentage of shares to promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares to total capital	39.21%	39.21%	39.21%	39.21%	39.21%	39.21%
Particulars		3 Months ended 31/12/2013					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	NIL	NIL				
	Received during the quarter	NIL	NIL				
	Disposed of during the quarter	NIL	NIL				
	Remaining unresolved at the end of the quarter	NIL	NIL				

NOTES:

- The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 30.01.2014
- The Accounting Standard 17 relating to Segment wise reporting is not applicable as the company operates in only one segment viz ,Pharmaceuticals
- There were no complaints from investors outstanding at the beginning of the Quarter ended 31st December 2013 and the Company has not received any complaints during the quarter ended 31st December 2013.
- Previous period / year figures have been regrouped wherever necessary.

Station: HYDERABAD
Date: 30.01.2014

For Concord Drugs Limited

S. Nagi Reddy
S. Nagi Reddy
Managing director

